

---

## Fluoguide Q3 2024 - Gearing up for high-impact catalysts in 2025e

Redeye comments on FluoGuide's Q3 2024 report, following its recent business update on FG001's planned development in head and neck cancer. We judge the company faces various high-impact clinical and business development catalysts in 2025e. We adapt our estimates and valuation to the company's recently announced plans. Our view of the investment case remains essentially unchanged.

[Read more and download the Research Update.](#)

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. [www.redeye.se/](http://www.redeye.se/)

### Attachments

---

[Fluoguide Q3 2024 - Gearing up for high-impact catalysts in 2025e](#)